There is usually no elevation of white blood cells after chemotherapy with albumin paclitaxel for bone metastasis of invasive lobular carcinoma of the breast. 1. Albumin paclitaxel is mainly an injectable drug, belonging to the albumin-binding type, which is mainly used to treat metastatic breast cancer patients who have failed combination chemotherapy or breast cancer patients who have relapsed within six months after adjuvant chemotherapy. The most obvious adverse reaction to the use of this drug is the decrease in white blood cells, as well as myelosuppressive reactions such as thrombocytopenia. 2. Under normal circumstances, the adverse reaction of leukopenia caused by the use of albumin paclitaxel can be gradually restored to the normal level in about one to two weeks. However, if the patient has a more serious albumin reduction and has not been recovered for a long time, timely treatment should be carried out.